{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:16:50Z","timestamp":1792819010682,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CRISPR\/Cas9 technology offers novel approaches for the development of new therapies for many unmet clinical needs, including a significant number of inherited monogenic diseases. However, in vivo correction of disease-causing genes is still inefficient, especially for those diseases without selective advantage for corrected cells. We reasoned that substrate reduction therapies (SRT) targeting non-essential enzymes could provide an attractive alternative. Here we evaluate the therapeutic efficacy of an in vivo CRISPR\/Cas9-mediated SRT to treat primary hyperoxaluria type I (PH1), a rare inborn dysfunction in glyoxylate metabolism that results in excessive hepatic oxalate production causing end-stage renal disease. A single systemic administration of an AAV8-CRISPR\/Cas9 vector targeting glycolate oxidase, prevents oxalate overproduction and kidney damage, with no signs of toxicity in <jats:italic>Agxt1<\/jats:italic><jats:sup>\u2212\/\u2212<\/jats:sup> mice. Our results reveal that CRISPR\/Cas9-mediated SRT represents a promising therapeutic option for PH1 that can be potentially applied to other metabolic diseases caused by the accumulation of toxic metabolites.<\/jats:p>","DOI":"10.1038\/s41467-018-07827-1","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T18:13:05Z","timestamp":1545070385000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":82,"title":["CRISPR\/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I"],"prefix":"10.1038","volume":"9","author":[{"given":"Nerea","family":"Zabaleta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miren","family":"Barberia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1139-4642","authenticated-orcid":false,"given":"Cristina","family":"Martin-Higueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Zapata-Linares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Betancor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Martinez-Turrillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Torella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Africa","family":"Vales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Olag\u00fce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaia","family":"Vilas-Zornoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Castro-Labrador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lara-Astiaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Prosper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-9854","authenticated-orcid":false,"given":"Eduardo","family":"Salido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Gonzalez-Aseguinolaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-1866","authenticated-orcid":false,"given":"Juan R.","family":"Rodriguez-Madoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"key":"7827_CR1","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.bbadis.2012.03.004","volume":"1822","author":"E Salido","year":"2012","unstructured":"Salido, E., Pey, A. L., Rodriguez, R. & Lorenzo, V. Primary hyperoxalurias: disorders of glyoxylate detoxification. Biochim. Et. Biophys. Acta - Mol. Basis Dis. 1822, 1453\u20131464 (2012).","journal-title":"Biochim. Et. Biophys. Acta - Mol. Basis Dis."},{"key":"7827_CR2","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","volume":"369","author":"P Cochat","year":"2013","unstructured":"Cochat, P. & Rumsby, G. Primary hyperoxaluria. N. Engl. J. Med. 369, 649\u2013658 (2013).","journal-title":"N. Engl. J. Med."},{"key":"7827_CR3","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00467-012-2329-z","volume":"28","author":"VO Edvardsson","year":"2013","unstructured":"Edvardsson, V. O. et al. Hereditary causes of kidney stones and chronic kidney disease. Pediatr. Nephrol. 28, 1923\u20131942 (2013).","journal-title":"Pediatr. Nephrol."},{"key":"7827_CR4","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1681\/ASN.2014070698","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp, K. et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria. J. Am. Soc. Nephrol. 26, 2559\u20132570 (2015).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7827_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/0014-5793(86)80563-4","volume":"201","author":"CJ Danpure","year":"1986","unstructured":"Danpure, C. J. & Jennings, P. R. Peroxisomal alanine:glyoxylate aminotransferase deficiency in primary hyperoxaluria type I. FEBS Lett. 201, 20\u201334 (1986).","journal-title":"FEBS Lett."},{"key":"7827_CR6","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1681\/ASN.V1291986","volume":"12","author":"E Leumann","year":"2001","unstructured":"Leumann, E. & Hoppe, B. The primary hyperoxalurias. J. Am. Soc. Nephrol. 12, 1986\u20131993 (2001).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7827_CR7","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/ki.2009.237","volume":"76","author":"S Fargue","year":"2009","unstructured":"Fargue, S. et al. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int. 76, 767\u2013773 (2009).","journal-title":"Kidney Int."},{"key":"7827_CR8","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1111\/j.1600-6143.2010.03271.x","volume":"10","author":"EJ Bergstralh","year":"2010","unstructured":"Bergstralh, E. J. et al. Transplantation outcomes in primary hyperoxaluria. Am. J. Transpl. 10, 2493\u20132501 (2010).","journal-title":"Am. J. Transpl."},{"key":"7827_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2215\/CJN.07430711","volume":"7","author":"J Harambat","year":"2012","unstructured":"Harambat, J. et al. Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy. Clin. J. Am. Soc. Nephrol. 7, 458\u2013465 (2012).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"7827_CR10","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1093\/ndt\/gfs078","volume":"27","author":"P Cochat","year":"2012","unstructured":"Cochat, P. et al. Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment. Nephrol. Dial. Transplant. 27, 1729\u20131736 (2012).","journal-title":"Nephrol. Dial. Transplant."},{"key":"7827_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1517\/13543784.2013.741587","volume":"22","author":"BB Beck","year":"2013","unstructured":"Beck, B. B., Hoyer-Kuhn, H., G\u00f6bel, H., Habbig, S. & Hoppe, B. Hyperoxaluria and systemic oxalosis: an update on current therapy and future directions. Expert. Opin. Investig. Drugs 22, 117\u2013129 (2013).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"7827_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00467-016-3553-8","volume":"32","author":"B Hoppe","year":"2017","unstructured":"Hoppe, B. et al. A randomised Phase I \/ II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Pediatr. Nephrol. 32, 781\u2013790 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"7827_CR13","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/sj.ki.5001707","volume":"70","author":"B Hoppe","year":"2006","unstructured":"Hoppe, B. et al. Oxalobacter formigenes: a potential tool for the treatment of primary hyperoxaluria type 1. Kidney Int. 70, 1305\u20131311 (2006).","journal-title":"Kidney Int."},{"key":"7827_CR14","doi-asserted-by":"publisher","first-page":"14406","DOI":"10.1073\/pnas.1408401111","volume":"111","author":"N Miyata","year":"2014","unstructured":"Miyata, N. et al. Pharmacologic rescue of an enzyme-trafficking defect in primary hyperoxaluria 1. Proc. Natl Acad. Sci. USA 111, 14406\u201314411 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7827_CR15","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1097\/TP.0b013e31816de49e","volume":"85","author":"J Jiang","year":"2008","unstructured":"Jiang, J. et al. Correction of hyperoxaluria by liver repopulation with hepatocytes in a mouse model of primary hyperoxaluria type-1. Transplantation 85, 1253\u20131260 (2008).","journal-title":"Transplantation"},{"key":"7827_CR16","doi-asserted-by":"publisher","first-page":"18249","DOI":"10.1073\/pnas.0607218103","volume":"103","author":"EC Salido","year":"2006","unstructured":"Salido, E. C. et al. Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer. Proc. Natl Acad. Sci. USA 103, 18249\u201318254 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"7827_CR17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/mt.2010.270","volume":"19","author":"E Salido","year":"2011","unstructured":"Salido, E. et al. Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer. Mol. Ther. 19, 870\u2013875 (2011).","journal-title":"Mol. Ther."},{"key":"7827_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/bs.apcsb.2015.10.001","volume":"102","author":"SA Syed Haneef","year":"2016","unstructured":"Syed Haneef, S. A. & Doss, GeorgePriya C. personalized pharmacoperones for lysosomal storage disorder: approach for next-generation treatment. Adv. Protein Chem. Struct. Biol. 102, 225\u2013265 (2016).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"7827_CR19","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1310\/hpj5107-553","volume":"51","author":"A Van Rossum","year":"2016","unstructured":"Van Rossum, A. & Holsopple, M. Enzyme replacement or substrate reduction? A review of gaucher disease treatment options. Hosp. Pharm. 51, 553\u2013563 (2016).","journal-title":"Hosp. Pharm."},{"key":"7827_CR20","doi-asserted-by":"crossref","unstructured":"Coutinho, M. F., Santos, J. I. & Alves, S. Less is more: Substrate reduction therapy for lysosomal storage disorders. Int. J. Mol. Sci. 17, pii: E1065 (2016).","DOI":"10.3390\/ijms17071065"},{"key":"7827_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/mt.2015.224","volume":"24","author":"C Martin-Higueras","year":"2016","unstructured":"Martin-Higueras, C., Luis-Lima, S. & Salido, E. Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I. Mol. Ther. 24, 719\u2013725 (2016).","journal-title":"Mol. Ther."},{"key":"7827_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/mt.2016.4","volume":"24","author":"C Dutta","year":"2016","unstructured":"Dutta, C. et al. Inhibition of glycolate oxidase with dicer-substrate sirna reduces calcium oxalate deposition in a mouse model of primary hyperoxaluria type I. Mol. Ther. 24, 1\u20139 (2016).","journal-title":"Mol. Ther."},{"key":"7827_CR23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1681\/ASN.2016030338","volume":"28","author":"A Liebow","year":"2017","unstructured":"Liebow, A. et al. An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J. Am. Soc. Nephrol. 28, 494\u2013503 (2017).","journal-title":"J. Am. Soc. Nephrol."},{"key":"7827_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/srep34060","volume":"6","author":"M Wang","year":"2016","unstructured":"Wang, M. et al. High throughput cell-based assay for identification of glycolate oxidase inhibitors as a potential treatment for Primary Hyperoxaluria Type 1. Sci. Rep. 6, 34060 (2016).","journal-title":"Sci. Rep."},{"key":"7827_CR25","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1136\/jmedgenet-2014-102529","volume":"51","author":"Y Frishberg","year":"2014","unstructured":"Frishberg, Y., Zeharia, A., Lyakhovetsky, R., Bargal, R. & Belostotsky, R. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria. J. Med. Genet. 51, 526\u2013529 (2014).","journal-title":"J. Med. Genet."},{"key":"7827_CR26","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00467-017-3741-1","volume":"32","author":"O Clifford-Mobley","year":"2017","unstructured":"Clifford-Mobley, O. et al. Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria. Pediatr. Nephrol. 32, 2159\u20132163 (2017).","journal-title":"Pediatr. Nephrol."},{"key":"7827_CR27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1002\/cpt.605","volume":"102","author":"M Cavaco","year":"2017","unstructured":"Cavaco, M. & Goncalves, J. Interactions between therapeutic proteins and small molecules: The Shared Role of Perpetrators aand Victims. Clin. Pharmacol. Ther. 102, 649\u2013661 (2017).","journal-title":"Clin. Pharmacol. Ther."},{"key":"7827_CR28","doi-asserted-by":"crossref","unstructured":"Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.\u00a0Science 337, 816\u2013822 (2012).","DOI":"10.1126\/science.1225829"},{"key":"7827_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.1232033","volume":"339","author":"P Mali","year":"2013","unstructured":"Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823\u2013826 (2013).","journal-title":"Science"},{"key":"7827_CR30","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.1231143","volume":"339","author":"L Cong","year":"2013","unstructured":"Cong, L. et al. Multiplex genome engineering using CRISPR\/Cas systems. Science 339, 819\u2013823 (2013).","journal-title":"Science"},{"key":"7827_CR31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","volume":"21","author":"DBT Cox","year":"2015","unstructured":"Cox, D. B. T., Platt, R. J. & Zhang, F. Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121\u2013131 (2015).","journal-title":"Nat. Med."},{"key":"7827_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cell.2016.10.044","volume":"168","author":"AC Komor","year":"2017","unstructured":"Komor, A. C., Badran, A. H. & Liu, D. R. CRISPR-based technologies for the manipulation of eukaryotic genomes. Cell 168, 20\u201336 (2017).","journal-title":"Cell"},{"key":"7827_CR33","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","volume":"31","author":"T Gaj","year":"2013","unstructured":"Gaj, T., Gersbach, C. A. & Barbas, C. F. ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering. Trends Biotechnol. 31, 397\u2013405 (2013).","journal-title":"Trends Biotechnol."},{"key":"7827_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cobme.2017.04.001","volume":"1","author":"D Katrekar","year":"2017","unstructured":"Katrekar, D., Hu, M. & Mali, P. Advances in CRISPR-Cas based genome engineering. Curr. Opin. Biomed. Eng. 1, 78\u201386 (2017).","journal-title":"Curr. Opin. Biomed. Eng."},{"key":"7827_CR35","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature10177","volume":"475","author":"H Li","year":"2011","unstructured":"Li, H. et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 475, 217\u2013221 (2011).","journal-title":"Nature"},{"key":"7827_CR36","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1126\/science.aad5725","volume":"351","author":"C Long","year":"2016","unstructured":"Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400\u2013403 (2016).","journal-title":"Science"},{"key":"7827_CR37","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1126\/science.aad5143","volume":"351","author":"CE Nelson","year":"2016","unstructured":"Nelson, C. E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403\u2013407 (2016).","journal-title":"Science"},{"key":"7827_CR38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1126\/science.aad5177","volume":"351","author":"M Tabebordbar","year":"2016","unstructured":"Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 407\u2013411 (2016).","journal-title":"Science"},{"key":"7827_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14716","volume":"8","author":"W Yu","year":"2017","unstructured":"Yu, W. et al. Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice. Nat. Commun. 8, 14716 (2017).","journal-title":"Nat. Commun."},{"key":"7827_CR40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nbt.3471","volume":"34","author":"H Yin","year":"2016","unstructured":"Yin, H. et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34, 328\u2013333 (2016).","journal-title":"Nat. Biotechnol."},{"key":"7827_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12642","volume":"7","author":"FP Pankowicz","year":"2016","unstructured":"Pankowicz, F. P. et al. Reprogramming metabolic pathways in vivo with CRISPR\/Cas9 genome editing to treat hereditary tyrosinaemia. Nat. Commun. 7, 12642 (2016).","journal-title":"Nat. Commun."},{"key":"7827_CR42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nbt.3469","volume":"34","author":"Y Yang","year":"2016","unstructured":"Yang, Y. et al. A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice. Nat. Biotechnol. 34, 334\u2013338 (2016).","journal-title":"Nat. Biotechnol."},{"key":"7827_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/srep44624","volume":"7","author":"KE Jarrett","year":"2017","unstructured":"Jarrett, K. E. et al. Somatic genome editing with CRISPR\/Cas9 generates and corrects a metabolic disease. Sci. Rep. 7, 44624 (2017).","journal-title":"Sci. Rep."},{"key":"7827_CR44","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature14299","volume":"520","author":"FA Ran","year":"2015","unstructured":"Ran, F. A. et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186\u2013190 (2015).","journal-title":"Nature"},{"key":"7827_CR45","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.gene.2012.07.009","volume":"506","author":"Z Yan","year":"2012","unstructured":"Yan, Z., Yan, H. & Ou, H. Human thyroxine binding globulin (TBG) promoter directs efficient and sustaining transgene expression in liver-specific pattern. Gene 506, 289\u2013294 (2012).","journal-title":"Gene"},{"key":"7827_CR46","doi-asserted-by":"crossref","unstructured":"Brinkman, E. K., Chen, T., Amendola, M. & Van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).","DOI":"10.1093\/nar\/gku936"},{"key":"7827_CR47","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.gendis.2016.07.003","volume":"3","author":"L Cai","year":"2016","unstructured":"Cai, L., Fisher, A. L., Huang, H. & Xie, Z. CRISPR-mediated genome editing and human diseases. Genes Dis. 3, 244\u2013251 (2016).","journal-title":"Genes Dis."},{"key":"7827_CR48","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/nmeth.3408","volume":"12","author":"V Iyer","year":"2015","unstructured":"Iyer, V. et al. Off-target mutations are rare in Cas9-modified mice. Nat. Methods 12, 479 (2015).","journal-title":"Nat. Methods"},{"key":"7827_CR49","unstructured":"Sang-Tae, K. Questioning unexpected CRISPR off-target mutations in vivo. Preprinted at https:\/\/www.biorxiv.org\/content\/early\/2017\/06\/30\/157925. (2017)."},{"key":"7827_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0001-8","volume":"6","author":"K Nakajima","year":"2016","unstructured":"Nakajima, K. et al. Exome sequencing in the knockin mice generated using the CRISPR\/Cas system. Sci. Rep. 6, 1\u20136 (2016).","journal-title":"Sci. Rep."},{"key":"7827_CR51","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191 (2016).","journal-title":"Nat. Biotechnol."},{"key":"7827_CR52","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","volume":"154","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Double nicking by RNA-guided CRISPR cas9 for enhanced genome editing specificity. Cell 154, 1380\u20131389 (2013).","journal-title":"Cell"},{"key":"7827_CR53","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/j.celrep.2017.08.075","volume":"20","author":"N Merienne","year":"2017","unstructured":"Merienne, N. et al. The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes. Cell Rep. 20, 2980\u20132991 (2017).","journal-title":"Cell Rep."},{"key":"7827_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15334","volume":"8","author":"G Petris","year":"2017","unstructured":"Petris, G. et al. Hit and go CAS9 delivered through a lentiviral based self-limiting circuit. Nat. Commun. 8, 15334 (2017).","journal-title":"Nat. Commun."},{"key":"7827_CR55","doi-asserted-by":"crossref","unstructured":"Charlesworth, C. et al. Identification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans. Preprinted at https:\/\/www.biorxiv.org\/content\/early\/2018\/01\/05\/243345. (2018).","DOI":"10.1101\/243345"},{"key":"7827_CR56","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nmeth.3993","volume":"13","author":"WL Chew","year":"2016","unstructured":"Chew, W. L. et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nat. Methods 13, 868\u2013874 (2016).","journal-title":"Nat. Methods"},{"key":"7827_CR57","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","volume":"26","author":"C Lai","year":"2018","unstructured":"Lai, C. et al. Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria. Mol. Ther. 26, 1983\u20131995 (2018).","journal-title":"Mol. Ther."},{"key":"7827_CR58","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1038\/mtna.2014.57","volume":"3","author":"NP Clayton","year":"2014","unstructured":"Clayton, N. P. et al. Antisense oligonucleotide-mediated suppression of muscle glycogen synthase 1 synthesis as an approach for substrate reduction therapy of pompe disease. Mol. Ther. - Nucleic Acids 3, e206 (2014).","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"7827_CR59","doi-asserted-by":"publisher","first-page":"36283","DOI":"10.1074\/jbc.M112.403360","volume":"287","author":"WC Lamanna","year":"2012","unstructured":"Lamanna, W. C. et al. A genetic model of substrate reduction therapy for mucopolysaccharidosis. J. Biol. Chem. 287, 36283\u201336290 (2012).","journal-title":"J. Biol. Chem."},{"key":"7827_CR60","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jhep.2015.09.014","volume":"64","author":"O Murillo","year":"2016","unstructured":"Murillo, O. et al. Long-term metabolic correction of Wilson\u2019s disease in a murine model by gene therapy. J. Hepatol. 64, 419\u2013426 (2016).","journal-title":"J. Hepatol."},{"key":"7827_CR61","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nbt.3628","volume":"34","author":"H Lindsay","year":"2016","unstructured":"Lindsay, H. et al. CrispRVariants charts the mutation spectrum of genome engineering experiments. Nat. Biotechnol. 34, 701\u2013702 (2016).","journal-title":"Nat. Biotechnol."},{"key":"7827_CR62","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.abb.2007.06.021","volume":"465","author":"C Vignaud","year":"2007","unstructured":"Vignaud, C., Pietrancosta, N., Williams, E. L., Rumsby, G. & Lederer, F. Purification and characterization of recombinant human liver glycolate oxidase. Arch. Biochem. Biophys. 465, 410\u2013416 (2007).","journal-title":"Arch. Biochem. Biophys."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07827-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07827-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T21:44:38Z","timestamp":1671572678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-07827-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["7827"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-07827-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,21]]},"assertion":[{"value":"30 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Eduardo Salido holds shares of Orfan Biotech. Gloria Gonzalez-Aseguinolaza is a founder and shareholder of Vivet Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5454"}}